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Mitochondria are evolutionary endosymbionts derived from bacteria. Thus, they bear 
molecules, such as mitochondrial DNA (mtDNA) that contains CpG DNA repeats and 
N-formyl peptides (FPs), found in bacteria. Upon cell necrosis or apoptosis, these 
molecules are released into the interstitial space and the circulation and recognized 
by the immune cells through the same receptors that recognize pathogen-associated 
molecular patterns, leading to inflammation. Other mitochondrial molecules are not of 
bacterial origin, but they may serve as danger-associated molecular patterns (DAMPs) 
when due to cell injury are translocated into inappropriate compartments. There they 
are recognized by pattern recognition receptors of the immune cells. Cytochrome c 
is such a molecule. In this review, experimental and clinical data are presented that 
confirms cytochrome c release into the extracellular space in pathological conditions 
characterized by cell death. This indicates that serum cytochrome c, which can be easily 
measured, may be a clinically useful marker for diagnosing and assessing the severity 
of such pathological entities. Reasonably, detection of high cytochrome c level into 
the circulation means release of various other molecules that serves as DAMPs when 
found extracellularly, the mtDNA and FPs included. Finally, because the release of this 
universally found compound into the extracellular space makes cytochrome c an ideal 
molecule to play the role of a DAMP per se, the available experimental and clinical data 
that support such a role are provided.
Keywords: cytochrome c, danger-associated molecular patterns, mitochondrial, apoptosis, necrosis
THe MiTOCHOnDRiOn AS A SOURCe OF  
DAnGeR-ASSOCiATeD MOLeCULAR PATTeRnS
The idea that the immune system has been evolved to discriminate non-infectious self from infectious 
non-self revolutionized our thinking about its function and regulation (1). Matzinger extended this 
perspective even further and proposed that the immune system is designed to react to danger signals, 
i.e., to signals of cell destruction or tissue demolition (2). Later, pattern recognition receptors (PRRs) 
were discovered on the surface or inside the immune cells able to recognize pathogen-associated 
molecular patterns (PAMPs) present in phylogenetically distant microbes, or danger-associated 
molecular patterns (DAMPs), i.e., self molecules present in inappropriate compartments due to cell 
destruction (3).
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Mitochondria are evolutionary endosymbionts derived from 
bacteria (4, 5), containing molecules that are normally present 
in prokaryotes and, consequently, under certain circumstances 
can be recognized by PAMPs’ specific PRRs eliciting an immune 
response. The best-defined mitochondrial DAMPs are the 
mitochondrial DNA (mtDNA) and the N-formyl peptides (FPs). 
Like bacterial DNA, mtDNA is characterized by the presence 
of unmethylated CpG repeats, recognized by the PRR toll-like 
receptor 9 (TLR9) (6). Injection of mtDNA intra-articularly 
induced a monocyte-dependent arthritis in mice, while mtDNA 
was also detected in the synovial fluid of patients with rheuma-
toid arthritis but not of control subjects (7). In an experimental 
model of injury-associated systemic inflammatory response 
syndrome, the role of the released mtDNA and its recogni-
tion by TLR9 in activation of polymorphonuclear neutrophils 
and establishment of this syndrome has been confirmed (8). 
Release of mtDNA and its recognition by TLR9 have also been 
incriminated in an experimental model of cardiomyopathy (9). 
Concerning FPs, it has been elaborated that they are encoded 
only by bacterial or mitochondrial genes due to initiation of 
protein synthesis with N-formylmethionine. FPs are recognized 
by specific receptors, such as the FP receptor 1 (FPR1) on human 
neutrophils, which by controlling neutrophils migration, activa-
tion, and degranulation is implicated in the pathogenesis of both 
infective and sterile inflammatory conditions (10). Utilizing 
the same experimental model of injury associated systemic 
inflammatory response syndrome as in the case of mtDNA, 
the role of the released FPs and their recognition by FPR1 in 
activation polymorphonuclear neutrophils and establishment of 
this syndrome has been validated (8). In experimental hemor-
rhagic shock or trauma, mitochondrial FPs were released into 
the circulation and recognized by FPRs on basophils inducing 
the systemic inflammatory response syndrome-associated 
hypotension. Circulating FPs were also recognized by FPRs on 
both mast cells and neutrophils inducing systemic inflammatory 
response syndrome-associated airway contraction and systemic 
inflammatory response syndrome-associated lung neutrophils 
infiltration, respectively (11, 12).
THe POTenTiAL OF CYTOCHROMe c 
TO Be A MiTOCHOnDRiAL DAMP OR 
A CLiniCALLY USeFUL MARKeR OF CeLL 
DeATH AnD ReLeASe OF OTHeR DAMPs 
inTO THe eXTRACeLLULAR SPACe
Cytochrome c is a small soluble electron carrier hemeprotein 
located in large amounts in the inner mitochondrial membrane. 
By transferring electrons from complex III to complex IV, 
cytochrome c facilitates cell energy production (13). Although 
is not encoded by mtDNA but by a gene located at the short arm 
of chromosome 7 (14), maintenance of the cytochrome c inside 
the mitochondrion is imperative, since its release into the cytosol 
results in cell apoptosis. During cell apoptosis cytochrome c 
is released into the cytoplasm where it binds and activates the 
apoptotic protease activating factor-1 (Apaf-1) allowing its 
binding to ATP and the formation of the ring-like apoptosome. 
Apoptosome through its caspase recruitment domain (CARD) 
binds, proteolyzes, and activates procaspase-9. Next, caspase-9 
proteolytically activates effector caspases-3, 6, and 7, key players 
in the execution-phase of cell apoptosis (15). Reasonably, in the 
occurrence of cell damage, cytochrome c could be released into 
the extracellular space, where it may serve as a DAMP, since many 
self-molecules when are translocated into inappropriate com-
partments play such a role (16). Thus, according to the location of 
cytochrome c, anti-inflammatory or pro-inflammatory properties 
may be attributed to it. Under normal conditions, cytochrome c 
resides into the mitochondria. Exodus of cytochrome c into the 
cytoplasm induces the non-inflammatory process of apoptosis, 
whereas once translocated into the extracellular space it may 
trigger inflammation. In parallel, in the latter case assessment of 
cytochrome c in extracellular space could be used as a marker 
of severe mitochondrial damage and cell death. Reasonably, the 
release of cytochrome c into the extracellular space during cell 
death is accompanied by and indicates the release of various 
intracellular components, the mtDNA and FPs included, that 
can be recognized by immune cell PRRs eliciting an immune 
response.
Plenty of experimental and clinical data recapitulated the 
release of cytochrome c from dying cells either due to apoptosis 
or necrosis. In splenocytes, immediately after heat shock-induced 
necrosis or within 2 h after an apoptotic insult, cytochrome c was 
released into the extracellular space in an intact monomeric form 
(17). In experimental resuscitation of cardiac arrest, circulating 
levels of cytochrome c increased progressively to levels 10-fold 
higher than in sham rats and correlated inversely with survival 
(18). A study of drug-induced hepatotoxicity revealed that 
cytochrome c can be used as a marker of liver injury (19). In 
experimental and clinical acute kidney injury, cytochrome c was 
also detected in the plasma and urine (20). Interestingly, release 
of cytochrome c into the culture medium due to staurosporine-
induced apoptosis of neuronal cells enhanced apoptosis further 
(21), and addition of exogenous cytochrome c in lymphocyte 
cultures induced apoptosis (22). This toxic effect of extracellular 
cytochrome c deserves further evaluation.
Besides experimental data, several clinical studies have con-
firmed release of cytochrome c into the extracellular space and, 
finally, into the circulation in various conditions characterized 
by cell death. Indeed, release of cytochrome c into the circula-
tion has been confirmed in patients with myocardial infarction 
(23). Serum level of cytochrome c was found increased in 
patients with several liver diseases. Mean serum cytochrome c 
concentration was 187.1  ng/mL in patients and only 39.8  ng/
mL in healthy controls. In these patients, cytochrome c level was 
correlated well with other biochemical markers of liver injury 
as well as with the necroinflammatory score and the apoptotic 
index of liver biopsies (24). In patients with acute liver failure, 
serum cytochrome c was elevated, correlated well with various 
biochemical markers of liver injury, the mitochondrial aspartate 
aminotransferase included. Mean serum cytochrome c concen-
tration was 10,686  pg/mL in patients with acute liver failure 
and only 112 pg/mL in healthy controls. Its level also paralleled 
with the severity of hepatic coma (25). There are also several 
studies remarking on the possible role of serum cytochrome 
FiGURe 1 | Cytochrome c as a marker of cellular damage and its potential role as a danger-associated molecular pattern. Serious cellular damage 
results in cell apoptosis or necrosis. In both cases, cytochrome c is released into the extracellular space and can be easily measured in the serum serving as a 
marker of severe cellular damage and death. Possibly, along with cytochrome c, other mitochondrial molecules are also released into the extracellular space. Among 
them are annotated some well-defined danger-associated molecular patterns (DAMPs), such as mitochondrial DNA, recognized by the toll-like receptor 9 (TLR9) 
into the endosomes of immune cells and N-formyl peptides, sensitized by the formyl peptide receptor 1 (FPR1) on the cell membrane of immune cells. Besides the 
above DAMPs, which resemble bacterial structures, there is evidence that cytochrome c, a universal self-molecule, when is inappropriately located into the 
extracellular space may behave as a DAMP and elicit an inflammatory response. However, further studies are required for supporting this role for cytochrome c and 
the responsible pattern recognition receptor(s) remain to be discovered.
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c as a prognostic marker in various types of cancer, with the 
higher levels showing high-turnover and, consequently, more 
aggressive tumors. On the other hand, elevated levels of serum 
cytochrome c after chemotherapy may be a good prognostic 
factor, indicating increased chemotherapy-induced cancer 
cell apoptosis (26–29). For instance, in patients with operable 
malignant tumors, median serum cytochrome c concentration 
was 20.6 ng/mL compared to 13.6 ng/mL in healthy volunteers. 
Survival was poorer in patients with serum cytochrome levels 
above 40 ng/mL and the optimal cut-off values for cytochrome 
c in preoperative patients with cancer were 22.7  ng/mL for 
metastasis, and 22.3  ng/mL for invasion (27). In a cohort of 
patients with non-small cell lung cancer, more than 13-fold 
increase in serum cytochrome c level was observed after the 
first cycle of conventional chemotherapy. Assessment of this 
increase has been proposed as a sensitive apoptotic marker 
in vivo, reflecting chemotherapy-induced cell death burden in 
patients with non-small cell lung cancer (28).
These aforementioned studies confirmed cytochrome c release 
into the extracellular space and ultimately into the blood in vari-
ous conditions characterized by cell death. Evidently, the more 
the cellular or tissue damage, the higher the serum cytochrome 
c level. Thus, cytochrome c may be a useful clinical marker for 
diagnosing and assessing the severity of such pathological enti-
ties. Reasonably, detection of high cytochrome c level into the 
circulation concurs with release of various other molecules that 
serve as DAMPs when found extracellularly, such as mtDNA 
and FPs. Finally, the release of this universal compound into the 
extracellular space makes cytochrome c an ideal molecule to act 
as a DAMP.
eviDenCe FOR THe ROLe OF 
CYTOCHROMe c PER SE AS A 
MiTOCHOnDRiAL DAMP
In most of the above studies that confirmed the release of 
cytochrome c into the circulation, the evaluated pathological enti-
ties were characterized not only by cell apoptosis and/or necrosis 
but also by local inflammation. However, there is evidence that 
serum cytochrome c levels increase in pathological conditions 
characterized by systemic inflammation as well, supporting its 
possible role as a DAMP.
The prototype of acute systemic inflammation is the systemic 
inflammatory response syndrome. Serum cytochrome c concen-
trations were markedly increased as measured in intensive care 
unit patients with systemic inflammatory response syndrome 
along with or at risk for multiple organ dysfunction syndrome. 
Mean serum cytochrome c concentration was 39.1  ng/mL in 
patients with acute pancreatitis, 12.09 ng/mL in septic patients, 
17.62 ng/mL in patients with septic shock, 2.13 ng/mL in surgical 
patients, 1.9 ng/mL in patients with severe burns and less than 
0.1 ng/mL in control subjects. Cytochrome c level correlated well 
with two representative organ dysfunction scores, APACHE II 
and multiorgan failure score. Interestingly, cytochrome c con-
centration increased earlier than the multiple organ failure score 
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in the exacerbation phase of the disease and remained high in 
non-survivors. On the contrary, in the convalescence phase of the 
disease, cytochrome c level decreased sharply in survivors (30). 
The prognostic value of the cytochrome c was also confirmed in 
acute encephalopathy with multiple organ failure (31).
Chronic hemodialysis could be characterized as a chronic 
systemic inflammatory condition. Many factors related to uremia 
per  se, hemodialysis procedure, complications of chronic renal 
disease, and therapeutic interventions for their treatment have 
been associated with the inflammation that characterizes hemo-
dialysis patients. In its turn, chronic inflammation contributes to 
atherosclerosis, malnutrition, resistance to erythropoietin treat-
ment, and decreased response to vaccination with T-cell depend-
ent antigens that characterize this population (32). Compared to 
healthy volunteers, in a cohort of free from infections, cancer or 
autoimmune diseases hemodialysis patients serum cytochrome 
c concentration was found markedly increased. Enzyme-linked 
immunosorbent assay revealed a serum cytochrome c concen-
tration of 1392.88  ±  905.24  pg/mL in hemodialysis patients; 
whereas in healthy volunteers, it was only 212.95 ±  91.71  pg/
mL. As expected, the level of the pro-inflammatory interleukin-6 
(IL-6) was also elevated (50.32 ± 35.89 vs. 14.27 ± 6.83 pg/mL). 
Interestingly, serum concentration of cytochrome c was strongly 
related to serum IL-6 level (r = 0.458), suggesting a cause and 
effect relationship (33). The source of serum cytochrome c in 
hemodialysis patients remains to be elucidated, yet both uremia 
and hemodialysis procedure may be implicated since they induce 
white blood cell apoptosis (34, 35).
Apart from clinical evidence for the role of cytochrome c as 
a DAMP, the most valid proof substantiating that role, derived 
from a controlled experimental study (36). In vitro stimulation 
of mouse spleen cells with exogenous cytochrome c resulted in 
activation of the transcription factor NF-κB along with increased 
concentrations of pro-inflammatory cytokines and chemokines 
into the culture medium. In vivo hisotopathological signs of 
arthritis were evident in mice injected intra-articularly with 
cytochrome c, with a synovitis characterized by macrophage 
antigen 1 positive (Mac-1+) cell infiltration. Mac-1 is present 
in polymorphonuclear neutrophils, NK cells, and monocytes/
macrophages. Depletion of neutrophils and monocytes resulted 
in abrogation of cytochrome c-induced arthritis. This experimen-
tal study confirms the role of cytochrome c as a DAMP, since 
its presence in inappropriate compartments elicited an immune 
response. Interestingly, the authors of this study rigorously tested 
the used cytochrome c for lipopolysaccharide (LPS) contamina-
tion and excluded any possible misinterpretation of the results 
due to an LPS effect. However, since the studies that support the 
role of cytochrome c as a DAMP are not robust, extra studies 
are required. In addition, further studies are necessary in order 
to define the PRR(s) that recognizes the cytochrome c, the exact 
type of the responding cells and the exact molecular mechanisms.
COnCLUSiOn
The conclusions of this mini-review are summarized in Figure 1.
All studies converge to the fact that in case of cell apoptosis 
or necrosis cytochrome c is released from the mitochondria 
into the extracellular space. Many studies confirmed that serum 
cytochrome c can be easily measured and used for diagnosing 
and assessing the severity of pathological entities characterized by 
cell death. However, different studies have shown diverse serum 
cytochrome c levels in various clinical entities and in healthy 
controls as well. The cut-off that discriminates normal from 
high-abnormal serum cytochrome c values has to be determined 
before the introduction of such a test into the clinical practice.
The greater the cell death, the higher the concentration of 
serum cytochrome c. Cell death leads to the concurrent release of 
cytochrome c and many other intracellular compounds into the 
extracellular space with some of them being also DAMPs, such 
as mtDNA and FPs. Thus, the circulating cytochrome c could be 
considered as an indirect but reliable marker of DAMPs release 
into the extracellular space and of the consequent systemic 
inflammation.
Finally, there is evidence for the role of cytochrome c as a 
DAMP. DAMPs are often normal self-molecules found into 
inappropriate compartments. Consequently, translocation of 
cytochrome c into the extracellular space provides the condition 
to act as an ideal DAMP. Cytochrome c is universally expressed 
in relatively large amounts in all cells and as such may play the 
role of a universal DAMP able of alarming the immune system for 
danger in any type of cell or tissue. In addition, cytochrome c is 
restricted within the mitochondria. Even its exodus into the cyto-
plasm triggers apoptosis. Thus, there are regulatory mechanisms 
for keeping cytochrome c into the mitochondria, whereas the 
extracellular compartment is definitely an inappropriate place for 
it. Nevertheless, the available well-designed experimental stud-
ies are sparse and additional studies are required about the role 
of cytochrome c as a DAMP. Certainly, further studies are also 
required in order to identify the PRR(s) sensitized by cytochrome 
c, the exact type of the responding cells and the exact molecular 
mechanisms.
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